PLK2 and Parkinson disease: An alternative pathway for inhibiting GSK-3β is phosphorylation by the polo-like kinase 2 (PLK2) at Point 40 [89], which is upregulated by protocatechuic aldehyde—an Nrf2 activator shown to ameliorate symptoms in models of Parkinson’s disease [90].